Baxter International Inc (BAX) 75.04 $BAX
Positive Data on Baxter's Trial for BAX 855 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 5:30PM CDT
Baxter International Inc. (BAX) conducted the Phase III trail with the aim to evaluate the effectiveness of BAX 855 in reducing annualized bleed rates during the treatment as compared to on-demand treatments.
Final Glance: Medical Devices companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Aug 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
PR Newswire - Thu Aug 21, 2:33PM CDT
Nektar Therapeutics (NASDAQ: NKTR) reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.
Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com
PRWeb - Thu Aug 21, 1:00PM CDT
The world wound care market is expected to grow from USD 15.6 billion in 2014 and reach USD 18.3 billion by 2019, posting a CAGR of 3.2% during the forecast period. The drivers of such growth include governments' contribution to the development of wound care products, rising obese and diabetic population, and surging ageing population. However, the growth could be restrained by high costs of state-of-the-art wound care products. Region-wise, North America leads the global wound care market, with the US grabbing the largest share. Asia is likely to exhibit the highest CAGR during 2014-2019 on the back of the increasing ageing population, rising awareness for wound healing products, growing diabetic wounds due to changes in lifestyle factors, and mushrooming population with pressure sores. Furthermore, a slew of overseas giant players are striving to establish their footprint in the Asian market, and such developments are expected to spur the region's wound care market to expand in the offing.
Baxter International Expands Dialyzers Facility in Alabama - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:10PM CDT
Baxter International (BAX) has been experiencing burgeoning demand for dialyzers across the globe as more people are getting inflicted by ESRD
Early Glance: Pharmaceuticals companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:
Baxter intends to increase production of dialyzers in Opelika site to support growth in end-stage renal disease therapy
M2 - Wed Aug 20, 10:31AM CDT
Medical products company Baxter International (NYSE:BAX) said on Tuesday that it plans to invest about USD300m to expand its state-of-the-art manufacturing facility in Opelika, Alabama, to help address the growing global demand for dialyzers, a critical component used in hemodialysis therapy (HD).
New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo
PR Newswire - Wed Aug 20, 7:40AM CDT
Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.
Baxter Announces Hemodialysis Dialyzer Expansion in Opelika, Alabama
M2 - Wed Aug 20, 4:01AM CDT
Baxter International Inc. (NYSE:BAX) announced today that it plans to expand its state-of-the-art manufacturing facility in Opelika, Ala., to help address the growing global demand for dialyzers, a critical component used in hemodialysis therapy (HD).
Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed
PRWeb - Wed Aug 20, 2:29AM CDT
AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Sodium Chloride IV.
Positive Data on Baxter's Trial for BAX 855 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 5:30PM CDT
Baxter International Inc. (BAX) conducted the Phase III trail with the aim to evaluate the effectiveness of BAX 855 in reducing annualized bleed rates during the treatment as compared to on-demand treatments.
Final Glance: Medical Devices companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Aug 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
PR Newswire - Thu Aug 21, 2:33PM CDT
Nektar Therapeutics (NASDAQ: NKTR) reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.
Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com
PRWeb - Thu Aug 21, 1:00PM CDT
The world wound care market is expected to grow from USD 15.6 billion in 2014 and reach USD 18.3 billion by 2019, posting a CAGR of 3.2% during the forecast period. The drivers of such growth include governments' contribution to the development of wound care products, rising obese and diabetic population, and surging ageing population. However, the growth could be restrained by high costs of state-of-the-art wound care products. Region-wise, North America leads the global wound care market, with the US grabbing the largest share. Asia is likely to exhibit the highest CAGR during 2014-2019 on the back of the increasing ageing population, rising awareness for wound healing products, growing diabetic wounds due to changes in lifestyle factors, and mushrooming population with pressure sores. Furthermore, a slew of overseas giant players are striving to establish their footprint in the Asian market, and such developments are expected to spur the region's wound care market to expand in the offing.
Baxter International Expands Dialyzers Facility in Alabama - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:10PM CDT
Baxter International (BAX) has been experiencing burgeoning demand for dialyzers across the globe as more people are getting inflicted by ESRD
Early Glance: Pharmaceuticals companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:
Baxter intends to increase production of dialyzers in Opelika site to support growth in end-stage renal disease therapy
M2 - Wed Aug 20, 10:31AM CDT
Medical products company Baxter International (NYSE:BAX) said on Tuesday that it plans to invest about USD300m to expand its state-of-the-art manufacturing facility in Opelika, Alabama, to help address the growing global demand for dialyzers, a critical component used in hemodialysis therapy (HD).
New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo
PR Newswire - Wed Aug 20, 7:40AM CDT
Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.
Baxter Announces Hemodialysis Dialyzer Expansion in Opelika, Alabama
M2 - Wed Aug 20, 4:01AM CDT
Baxter International Inc. (NYSE:BAX) announced today that it plans to expand its state-of-the-art manufacturing facility in Opelika, Ala., to help address the growing global demand for dialyzers, a critical component used in hemodialysis therapy (HD).
Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed
PRWeb - Wed Aug 20, 2:29AM CDT
AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Sodium Chloride IV.
